Cookson Peirce & Co. Inc. Takes $746,000 Position in ResMed Inc. $RMD

08 Jun 2026, 07:49 by Tristan Rich · The Markets Daily

Cookson Peirce & Co. Inc. acquired a new stake in ResMed Inc. (NYSE:RMD – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,098 shares of the medical equipment provider’s stock, valued at approximately $746,000.

A number of other large investors also recently modified their holdings of RMD. Jones Financial Companies Lllp boosted its position in shares of ResMed by 52.6% in the first quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock valued at $645,000 after acquiring an additional 994 shares during the period. Arrowstreet Capital Limited Partnership bought a new position in shares of ResMed in the second quarter valued at approximately $389,000. Brown Advisory Inc. boosted its position in shares of ResMed by 17.8% in the second quarter. Brown Advisory Inc. now owns 1,586 shares of the medical equipment provider’s stock valued at $409,000 after acquiring an additional 240 shares during the period. Cresset Asset Management LLC bought a new position in shares of ResMed in the second quarter valued at approximately $206,000. Finally, Alliancebernstein L.P. lifted its position in ResMed by 24.2% during the second quarter. Alliancebernstein L.P. now owns 286,078 shares of the medical equipment provider’s stock valued at $73,808,000 after purchasing an additional 55,790 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on RMD. Weiss Ratings lowered shares of ResMed from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. JPMorgan Chase & Co. began coverage on shares of ResMed in a research report on Wednesday, April 15th. They set an “overweight” rating for the company. Wall Street Zen lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Wells Fargo & Company dropped their target price on shares of ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Finally, Robert W. Baird set a $225.00 target price on shares of ResMed in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $286.18.

View Our Latest Stock Analysis on ResMed

ResMed Trading Down 0.0%

Shares of ResMed stock opened at $195.95 on Monday. ResMed Inc. has a 1 year low of $180.26 and a 1 year high of $293.81. The firm has a market cap of $28.42 billion, a PE ratio of 18.90, a PEG ratio of 1.25 and a beta of 0.80. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.01 and a quick ratio of 2.33. The company has a 50 day simple moving average of $213.11 and a two-hundred day simple moving average of $237.15.

ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. The firm had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.42 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The business’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.37 EPS. Analysts expect that ResMed Inc. will post 11.13 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed’s payout ratio is presently 23.14%.

Insider Buying and Selling

In other news, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $225.00, for a total value of $450,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $207.82, for a total transaction of $1,037,229.62. Following the completion of the sale, the chief executive officer owned 466,223 shares of the company’s stock, valued at approximately $96,890,463.86. The trade was a 1.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 11,982 shares of company stock valued at $2,612,700. Company insiders own 0.65% of the company’s stock.

ResMed Profile

(Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.